Processa Pharmaceuticals Inc PCSA.OQ PCSA.O is expected to report results on October 28 (estimated) for the period ending September 30 2025
LSEG's mean analyst estimate for Processa Pharmaceuticals Inc is for a loss of 8 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Processa Pharmaceuticals Inc is $1.00, about 69.4% above its last closing price of $0.31
This summary was machine generated October 24 at 11:58 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)